The Monoclonal Antibody Medications in inflammatory Arthritis: stopping or continuing in pregnancy (MAMA) trial

Research summary

The Monoclonal Antibody Medications in inflammatory Arthritis (MAMA) trial is designed to address the significant uncertainty and resulting variation in practice surrounding the effects of continuing or stopping biologics during pregnancy. There are no randomised trials which compare stopping or continuing biologics in head-to-head studies in an Autoimmune Inflammatory Arthritis (AIA) population. This study aims to fill the gap in evidence and enable evaluation of arthritis disease activity,pregnancy,and infant outcomes in women randomly allocated to continuing their biologic medication throughout pregnancy,or to stopping their biologic medication prior to 28 completed weeks’ gestation in a pragmatic,randomised controlled trial. The trial will assess arthritis disease activity,pregnancy,and infant outcomes in each arm of the study. Exploring the infant immunological response to these agents will also add to the body of evidence regarding their safety and may provide valuable insights into the effect of in-utero exposure to previously sparsely studied classes of biologics.

Principal Investigator

Dr Lucy Mackillop

Contact us

Email: osprea@wrh.ox.ac.uk

IRAS number

1009876